Skip to main content

Table 1 Patient demographics

From: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation

 

Item

IM Olz, 10 mg

IM Placebo

Total

pvaluea

(N=45)

(N=45)

(N=90)

Age, years

N

45

45

90

.812

Mean

46.4

47.0

46.7

SD

11.7

12.1

11.9

Min

20

23

20

Median

50.0

45.0

47.0

Max

63

65

65

Gender, n (%)

Male

21 (46.7)

23 (51.1)

44 (48.9)

.833

Female

24 (53.3)

22 (48.9)

46 (51.1)

BMI, kg/m2

N

45

45

90

.360

Mean

23.9

23.0

23.4

SD

4.9

4.1

4.5

Min

16.1

14.3

14.3

Median

23.4

22.5

23.0

Max

38.4

35.1

38.4

Age at onset, years

N

44

45

89

.215

Mean

24.7

27.2

25.9

SD

9.4

9.3

9.4

Min

15

16

15

Median

22.0

25.0

23.0

Max

49

57

57

  1. Abbreviations: BMI=body mass index; IM Olz=intramuscular olanzapine; Max=maximum; Min=minimum; N= number of patients in analysis set; n= number of patients in subset; SD=standard deviation.
  2. a p value: Student's t test for continuous data, Fisher's exact test for categorical data.